An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects

[1] Block GA(2000)Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients Clin Nephrol 54 318-324

[2] Goodman WG(2001)Recent developments in the management of secondary hyperparathyroidism Kidney Int 59 1187-1201

[3] Delmez JA(1989)Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium J Clin Invest 83 1349-1355

[4] Tindira C(2011)Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism Kidney Int 79 112-119

[5] Grooms P(2004)Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516-1525

[6] Dusso A(2005)Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means Pediatr Nephrol 20 399-403

[7] Windus DW(2005)Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800-807

[8] Slatopolsky E(2005)Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl Nephrol Dial Transplant 20 2186-2193

[9] Wesseling-Perry K(1998)Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci USA 95 4040-4045

[10] Pereira RC(1993)Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid Nature 366 575-580

[1] Block GA(2000)Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients Clin Nephrol 54 318-324

[2] Goodman WG(2001)Recent developments in the management of secondary hyperparathyroidism Kidney Int 59 1187-1201

[3] Delmez JA(1989)Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium J Clin Invest 83 1349-1355

[4] Tindira C(2011)Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism Kidney Int 79 112-119

[5] Grooms P(2004)Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis N Engl J Med 350 1516-1525

[6] Dusso A(2005)Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic means Pediatr Nephrol 20 399-403

[7] Windus DW(2005)Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study J Am Soc Nephrol 16 800-807

[8] Slatopolsky E(2005)Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl Nephrol Dial Transplant 20 2186-2193

[9] Wesseling-Perry K(1998)Calcimimetics with potent and selective activity on the parathyroid calcium receptor Proc Natl Acad Sci USA 95 4040-4045

[10] Pereira RC(1993)Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid Nature 366 575-580